OncoMatch/Clinical Trials/NCT04625907
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Is NCT04625907 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for rhabdomyosarcoma.
Treatment: Irinotecan · Actinomycin D · Doxorubicin · Ifosfamide · Vincristine · Vinorelbine · Cyclophosphamide · Temozolomide · Regorafenib — FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)
Check if I qualifyExtracted eligibility criteria
Cancer type
Rhabdomyosarcoma
Prior therapy
Cannot have received: stem cell transplant
Prior allo- or autologous Stem Cell Transplant
Cannot have received: regorafenib (regorafenib)
Prior regorafenib
Cannot have received: temozolomide (temozolomide)
Prior temozolomide
Lab requirements
Blood counts
Absolute neutrophil count ≥1.0x 10^9/L; Platelets ≥ 80 x 10^9/L
Kidney function
estimated or measured creatinine clearance ≥60 ml/min/1.73 m2
Liver function
Total bilirubin ≤ 1.5 x ULN for age (unless Gilbert's syndrome); ALT or AST < 2.5 x ULN for age (IRIVA); ALT or AST >3.0 x ULN [excluded, CT3]; Bilirubin, Total >1.5 x ULN [excluded, CT3]; total bilirubin is allowed up to 3 x ULN if Gilbert's syndrome is documented
Cardiac function
Fractional Shortening ≥ 28% (CT1a); Absence of severe vincristine neuropathy; No unstable angina, recent MI, cardiac failure NYHA ≥2, congestive heart failure (Modified Ross ≥2), or cardiac arrhythmias requiring antiarrhythmic therapy (CT3)
Adequate hepatic function: Total bilirubin ≤ 1.5 x ULN for age (unless Gilbert's syndrome); ALT or AST < 2.5 x ULN for age; Absolute neutrophil count ≥1.0x 10^9/L; Platelets ≥ 80 x 10^9/L; Adequate renal function: estimated or measured creatinine clearance ≥60 ml/min/1.73 m2; Fractional Shortening ≥ 28%; Absence of severe vincristine neuropathy; No unstable angina, recent MI, cardiac failure NYHA ≥2, congestive heart failure (Modified Ross ≥2), or cardiac arrhythmias requiring antiarrhythmic therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify